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One of the most common metabolic disorders among both men and women is 
hyperprolactinemia. Hyperprolactinemia, by definition, is the persistent elevation of 
serum prolactin levels (Kaye 265). Prolactin is a hormone produced and secreted by 
lactotroph cells in the anterior pituitary gland (Kaye 266). The normal upper limit serum 
prolactin level is 20nglmL in women and slightly lower in men (Kaye 265). Prolactin 
hormone is similar to growth hormone but has several different functions in the body. It 
is known that prolactin induces lobuloalveolar growth of the mammary gland and 
stimulates lactogenesis, commonly referred to as milk production (Prolactin). It is also 
known that prolactin has molecular heterogeneity. This means that there are different 
molecular forms of prolactin with varying degrees of bioactivity (Crosignani 1117). 
Hyperprolactinemia can be caused by numerous factors from certain drugs to adenomas. 
Two specific causes of hyperproiactinemia, ethanol consumption and administration of 
anti-psychotics, have been examined to determine exactly what causes increased 
prolactin production. It is important to study the molecular aspects of increased prolactin 
production in order to effectively treat those affected. The disorder has also been shown 
to be asymptotic or symptomatic. Symptoms range widely and are more common in 
women than in men. Though symptoms can suggest hyperprolactinemia, laboratory tests 
are necessary to confirm a diagnosis. Once diagnosis is confirmed there are several 
different treatment options for patients and physicians to consider. Treatment ranges 
from observation to surgery depending on the severity and cause of the disorder. There 
are no defined preventative measures for hyperprolactinemia. There are, however, 
suggestions such as ceasing ingestion of certain medications known to cause elevated 
prolactin levels if abnonnal serum prolactin levels are reached. Another aspect of 
hyperprolactinemia is its involvement in autoimmune diseases. There are indications that 
high levels of serum prolactin in the body effect aspects of immune function. 
Hyperprolactinemia is thought to playa role in Sjogren's syndrome and systemic lupus 
erythematosus, an auto-immune thyroiditis, as well as other auto-immune diseases 
(Velkeniers 1102). The immune system is also thought to produce auto-antibodies 
against high levels of serum prolactin. 
The onset of hyperprolactinemia can be caused by numerous things. 
Hyperprolactinemic patients can be broken down into three groups: those without a 
pituitary lesion, those with a microadenoma, and those with a macroadenoma (Rebar 
1100-01). When no pituitary lesion is present, high levels of prolactin can be caused by 
numerous things. Physiologically, pregnancy, early nursing, stress, sleep, nipple 
stimulation, and the ingestion of certain foods can cause serum levels to increase above 
normal (Biller & Luciano 1078). There are also several medications that can cause 
hyperprolactinemia. Dopamine receptor antagonists and dopamine-depleting agents can 
cause prolactin levels to increase. (Luciano 1087) Prolactin levels are regulated through 
a mechanism where hypothalamic dopamine inhibits the synthesis and secretion of 
prolactin by binding receptors on lactotrophs (prolactin). Ifthere is a lack of dopamine in 
the body, excess prolactin can be produced and secreted. Honnones such as estrogen, 
antiandrogens, and opiates can also increase serum prolactin levels. Several preexisting 
diseases are also known to increase serum prolactin levels. Hypothalamic and pituitary 
stalk disease, primary hypothyroidism, chronic renal failure, cirrhosis, chest wall trauma, 
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and seizures can all cause hyperprolactinemia (Luciano 1087). Cirrhosis and chronic 
renal failure cause hyperprolactinemia by inducing an increased level of prolactin 
secretion and a decreased metabolic clearance rate. Often times when there is no 
adenoma present in hyperprolactinemic patients an exact cause for elevated prolactin 
levels cannot be pinpointed. (Kaye 265) 
The major causes of hyperproIactinemia are adenomas. There are two different 
types of adenomas associated with hyperprolactinemia: microadenomas and 
macroadenomas. Microadenomas are defined as lesions less than one centimeter in 
diameter and macroadenomas are defined as lesions greater than or equal to one 
centimeter (Rebar 1102). Collectively, the different types of pituitary lesions causing 
hyperprolactinemia are referred to as prolactinomas. Hyperprolactinemia caused by a 
microadenoma is considered less threatening to a patient than macroadenoma induced 
hyperprolactinemia because macroadenomas are more prone to increasing in size. 
Adenomas, certain drugs, and even certain foods have all been shown to cause 
hyperprolactinemia. While these causes ofhyperprolactinemia are all apparent, there are 
underlying causes of increased prolactin production. The molecular causes of increased 
prolactin production are oftentimes studied in laboratory animals. If scientists can 
specifically determine what causes increased prolactin production and cell proliferation 
they may be able to better treat hyperprolactinemic patients. It has been suggested that 
alcohol consumption can increase the amount of prolactin produced in the pituitary 
causing hyperprolactinemia. A study using female rats was conducted at Rutgers, The 
State University ofNew Jersey, to determine how alcohol (ethanol) affects lactotrope 
growth and prolactin production. Anti-psychotics are another cause of increased 
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prolactin production. A paper entitled Prolactin Levels and Adverse Events in Patients 
Treated with Risperidone (Kleinberg) examines the effect of Risperidone on prolactin 
levels and the risk associated with anti-psychotic drug induced hyperprolactinemia. 
Studies done on two drugs, alcohol and anti-psychotics, examine ways in which 
hyperprolactinemia is brought about at the molecular level and the consequences of the 
disorder. 
Although it is known that alcoholism can cause hyperprolactinemia the 
mechanism by which this occurs is unknown. A study performed at the Center of 
Alcohol Studies and Department of Animal Sciences at Rutgers University and reported 
in a paper entitled Ethanol Induces Hyperprolactinemia by Increasing Prolactin Release 
and Lactotrope Growth in Female Rats (De) examined whether increased pituitary 
production of prolactin was caused by an increase in cell number and/or cell production 
of prolactin in the pituitary. Several clinical studies have shown chronic alcoholism 
elevates serum prolactin levels. Alcohol has also been demonstrated to raise serum 
prolactin in nonhuman primates and various laboratory animals in studies conducted in 
the past. The positive correlation between alcohol and increased serum prolactin levels 
led researchers to investigate exactly how ethanol increased prolactin production. This 
information could lead to a better understanding of how to treat elevated prolactin levels. 
In this study, scientists addressed: 
Whether alcohol-induced hyperprolactinemia is the result of increased 
pituitary production of prolactin as a result of increased cell number 
and/or increased cell production of prolactin in the pituitary ... and 
whether ethanol acts directly on the pituitary lactotropes and whether 
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ethanol's actions on lactotropes is dependent on the presence of estradiol 
(De 1421-2). 
Estradiol is a potent estrogen hormone synthesized in the ovaries. It is present in the 
placenta, testis, and possibly the adrenal cortex. (On-line Medical Dictionary) 
The affect of alcohol (ethanol) on rats in various conditions was tested in this 
study. Control strains were used for comparison to ethanol fed rats. Fischer-344 rats 
were kept in a controlled environment and used for this experiment. A portion of the rats 
were ovariectomized while the remaining rats kept their ovaries. A portion of the 
ovariectomized rats had an estradiol capsule implanted inside of them during surgery. 
The remaining ovariectomized rats had empty capsule inserts and served as controls to 
compare the effects of estradiol on the action of ethanol. At the end of the experiment, 
the test rats were euthenized and their trunk blood and pituitary glands were extracted for 
analysis. The anterior pituitaries of twenty-four ovariectomized rats with estradiol 
capsules were treated for lactotrophic cell extraction. These cells were treated with 
various doses of ethanol and their level of prolactin production was measured by 
radioimmunoassay (RIA). RIA is an analysis system for testing antigen-antibody 
reactions using radioactivity to label the antibody or antigen to determine the relative 
abundance of the desired antibody or antigen (On-line Medical Dictionary). Other 
lactotropes were treated with ethanol and/or estradiol and assayed for cell proliferation. 
The mitogenic affect of ethanol was determined in this experiment by measuring 
the wet weight and protein content of the pituitary. In cyclic female rats it was 
demonstrated that an ethanol diet significantly increased the weight of the anterior 
pituitary when compared to those rats fed diets without ethanol after fifteen days. 
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Ethanol treatments were also shown to increase the amount of protein produced by the 
anterior pituitary. After thirty days of an ethanol diet, rats showed an even more 
significant increase in wet weight and protein content. The total protein level of rats 
treated with ethanol was significantly higher in estradiol treated rats than in those 
administered ethanol alone indicating that estradiol potentates the effects of ethanol. 
Analysis of the pituitary of ethanol fed rats revealed an increased number of 
proliferating lactotrophic cells after fifteen days. The serum prolactin levels ofrats fed 
an ethanol diet and a regular diet were also compared. Serum levels were higher in all 
rats fed an ethanol diet. Overall, rats administered estradiol has serum prolactin levels 
higher than cyclic and ovariectomized rats that were not given estradiol capsules. 
The effect of ethanol on isolated lactotropes and mixed anterior pituitary cell 
cultures was also analyzed in vitro. It was previously shown that estradiol increases 
lactotropic cell proliferation by increasing cell-to-cell communication among pituitary 
cells. Cultures of cells were tested to determine if ethanol similarly affected cell 
proliferation. Mixed anterior pituitary cells showed increased proliferation in the 
presence of estradiol and ethanol together. A culture of enriched lactotropes alone did 
not show an increase in cell proliferation with the addition of ethanol and estradiol. The 
data gathered in this experiment demonstrated that "ethanol increased lactotrope 
proliferation only when these cells maintain communication with other pituitary cells" 
(De 1426). The amount of prolactin secreted by cells in culture was also analyzed under 
different conditions. Cells treated with ethanol and estradiol together produced much 
higher levels of prolactin than those cells treated with ethanol alone. 
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All of the results compiled in the duration of this experiment indicated that 
ethanol affected the production of prolactin in a fashion similar to that of estradiol. 
Ethanol was shown to increase both serum prolactin levels and the number of mitogenic 
lactotropes in the anterior pituitary in a time dependent fashion. Administration of 
ethanol also appeared to potentate the affects of estradiol in the rats. Both ethanol and 
estradiol were shown to increase prolactin levels by directly affecting lactotrophic cells 
and increase the number of proliferating lactotropes indirectly by altering cell-to-cell 
communication between different cell types in the anterior pituitary. The increase in the 
mitogenic action oflactotropes was proven in this experiment by several examples. First, 
the wet weight and protein content of the anterior pituitaries both increased indicating a 
higher number of cells present. Secondly, the amount of cells shown to be undergoing 
DNA synthesis after ethanol administration indicated that the number of lactotropes 
dividing in the pituitary approximately doubled. Ethanol was also shown to increase the 
amount of prolactin excreted from lactotropes. Because ethanol increased prolactin 
production in vitro in enriched lactotropes alone it is believed that ethanol directly acts on 
the cells. It is still not clear exactly how ethanol causes increased prolactin release. It 
was shown that estradiol promoted the amount of prolactin released by cells administered 
ethanol. This only occurred in mixed cell cultures indicating that cell-to-cell 
communication may be necessary for ethanol and estradiol to fully interact to increase 
prolactin levels and lactotrope proliferation. 
The exact mechanism in which ethanol affects lactotropes has not yet been 
determined. It is believed that it may involve cytokines, or intercellular mediators, 
produced locally in the pituitary. One cytokine, Transforming Growth Factor -(beta]-l 
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(TGF-[beta]-I), has been shown to inhibit prolactin production and cell proliferation. 
The production of this cytokine is inhibited by estradiol administration and further 
reduced by ethanol administration. This has lead researchers to hypothesize that 
ethanol's affect on the pituitary may be connected to modification ofTGF-[beta]-1 
production and action. The data gathered in this experiment suggests that "ethanol 
consumption may promote or aggravate the pathology of existed pituitary tumors" (De 
1429). 
Anti-psychotics are used to treat a number of illnesses and are often accompanied 
by several adverse side affects. One side effect noted with the use of all neuroleptics, or 
anti-psychotics, is increased serum prolactin levels. These drugs act as dopamine 
receptor antagonists. By definition, antagonists are drugs that bind a cell receptor 
without eliciting a biological response (On-line Medical Dictionary). They inhibit the 
action of dopamine on D2 receptors on the surface of pituitary lactotropes causing an 
increase in prolactin production (Kleinberg 57). Early dopamine blocking drugs used to 
treat psychosis were all shown to relieve psychosis, cause extrapyramidal side effects, 
and elevate prolactin levels by antagonizing D2 receptors. It was first shown in 1971 that 
chlorpromazine, one of the earliest dopamine-blocking drugs caused prolactin levels to 
increase above normal in humans (Kleinberg 57). More recently drugs such as 
Risperidone, Olanzapine, and Clozapine have been used to treat psychosis. These drugs 
are combined serotonin (5-hydroxytryptamine-2-[5-HT2]) and dopamine (5-HT21D2) 
receptor antagonists. These drugs, which have a lower incidence of extrapyramidal side 
effects, still increase serum prolactin levels leading researchers to explore the causes of 
increased prolactin production for the sake of patients' health. (Kleinberg 57-8) 
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The main concern with anti-psychotic drug induced hyperprolactinemia is the 
possible side effects brought about by increased prolactin levels. There are several side 
effects of concern. These include amenorrhea, galactorrhea, and decreased libido in 
women, and erectile dysfunction, ejaculatory dysfunction, gynecomastia, and decreased 
libido in men (Kleinberg 57-8). It was previously shown that drugs with a mode of 
action similar to Risperidone increased serum prolactin levels to a greater extent than 
previously used neuroleptics. Studies were conducted on Risperidone and haloperidol to 
determine if the side effects from hyperprolactinemia occurring in patients treated with 
HT2/02 receptor antagonists (Risperidone) was more severe than those occurring in 
patients treated with O2 receptor antagonists (haloperidol). There was great concern that 
"Risperidone could cause an unacceptably high incidence of amenorrhea and galactorrhea 
as a result of elevated serum prolactin levels" (Kleinberg 58). 
Because of the long term affects of disorders such as amenorrhea it was important 
to determine whether or not it was safe to administer Risperidone to psychotic patients. 
Amenorrhea and galactorrhea both cause a reduction in sex steroids. Prolonged reduction 
of estrogen, for example, can lead to premature osteoporosis. The compiled data suggests 
that Risperidone treatment, while it does raise prolactin levels higher than other anti­
psychotics, is safe for the long term health of patients. This is also beneficial because 
there are less extrapyramidal side effects incurred during treatment with Risperidone as 
compared to anti-psychotics that are only O2 antagonists. It was also important to rule 
out a greater incidence ofhyperprolactinemic side effects for two other reasons. First, 
detrimental sexual side effects oftentimes cause patients to stop taking their medication. 
Side effects such as sexual dysfunction and ejaculatory or erectile dysfunction inhibit 
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sexual fulfillment and may lead to infertility. These side effects are detrimental to the 
already tragi Ie mental state of people taking these medications. Secondly, 
hyperprolactinemia induced by anti-psychotics could mask a prolactinoma or other 
non neuroleptic cause ofhyperprolactinemia. It was concluded that all patients with 
elevated serum prolactin levels should be monitored for existing causes of 
hyperprolactinemia, such as a prolactinoma, regardless of medication they are taking. If 
such a condition is found to exist, it should be treated along with the patient's psychosis. 
(Kleinberg 62) 
Though hyperprolactinemia has been diagnosed in less than one percent of the 
general population, it is still thought of as one of the most common pituitary disorders 
(Kaye 265). In some patients the disorder is asymptomatic and in others a variety of 
symptoms are apparent. In the early 1970's it was discovered that high levels of prolactin 
are associated with abnormal menstrual cycles in females and gonadal disorders in males 
(Luciano 1085). Symptoms of hyperprolactinemia are generally more apparent in women 
than in men. Hypogonadism is commonly associated with hyperprolactinemia and can 
cause many of the symptoms associated with raised prolactin levels. These symptoms 
can include oligomenorrhea or amenorrhea, and/or galactorrhea. (Kaye 265) Amenorrhea 
is a lack of menstrual cycles and galactorrhea is excessive or spontaneous secretion of 
milk (Prolactin). Oligomenorrhea is infrequent menstruation with markedly diminished 
menstrual flow (On-line Medical Dictionary). Developing amenorrhea as a result of 
hyperprolactinemia must be considered because it puts women at greater risk of 
developing osteoporosis (Kaye 265). Other symptoms of hyperprolactinemia in women 
can include decreased libido, hirsutism, acne, infertility, habitual abortion, and osteopenia 
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(Biller & Luciano 1080). Hirsutism is a condition of abnormal hairiness, most commonly 
involving male hair pattern distribution in women (On-line Medical Dictionary). 
Infertility due to hyperprolactinemia is most often caused by chronic anovulation, 
defective folliculogenesis, and luteal phase inadequacy (Jones 835). According to the 
On-line Medical Dictionary, the luteal phase is the post ovulatory phase of a woman's 
menstrual cycle. During this phase progesterone is produced which causes the uterine 
lining to secrete substances to support the implantation and growth of an early embryo. 
When a macroadenoma is present in a patient they may also experience mass 
effects such as headaches, visual loss, cranial neuropathies, hypopituitarism, seizures, and 
cerebrospinal fluid rhinorrhea (Biller & Luciano 1080). For clarification: Cranial 
neuropathies involve functional disturbances and/or pathological changes in the 
peripheral nervous system and is also the term used to designate noninflammitory lesion 
in the peripheral nervous system; hypopituitarism is a medical condition where the 
pituitary gland produces lower than normal levels of hormones; and cerebrospinal fluid 
rhinorrhea is defined as the discharge of cerebrospinal fluid through the nose (On-line 
Medical Dictionary). 
Men normally show fewer symptoms ofhyperprolactinemia than women and the 
disorder itself is less common in men. Symptoms in men can include decreased sperm 
production, decreased libido and energy, gynecomastia, loss of pubic hair, osteoporosis, 
loss of muscle mass, and impotence (Biller & Luciano 1080). Gynecomastia is the 
excessive development of the male breasts (On-Line Medical Dictionary). Most often, 
hyperprolactinemia is associated with hypogonadism in men, which can cause impotence 
in the advanced stage (Jones 836). 
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In order for a physician to diagnose hyperprolactinemia, a medical examination 
and laboratory testing are necessary. Most patients with diagnosed hyperprolactinemia 
go to a physician only after showing symptoms such as infertility, irregular periods, or 
impotence. In many cases, hyperprolactinemia may go undiagnosed due to a lack of 
symptoms. In order to determine whether or not a patient has hyperprolactinemia, and 
the underlying cause of the disorder, the patient should have a complete medical 
examination by a physician and laboratory testing of hormone levels. 
The physical examination conducted when a patient is suspected of having 
hyperprolactinemia should be very extensive. If a patient is showing symptoms of 
hyperprolactinemia, such as galactorrhea or amenorrhea, a blood test should be 
administered to measure serum prolactin levels and test for pregnancy (Biller & Luciano 
1080). If prolactin levels are high and the pregnancy test is negative, a second test should 
be administered to determine whether or not prolactin levels are consistently high. This 
needs to be done because stress and exercise can temporarily elevate prolactin levels 
(Kaye 266). Exercise, stress, and pregnancy induced hyperprolactinemia are examples of 
physiologic hyperprolactinemia and oftentimes prolactin levels wi II return to normal 
naturally (Biller 1096). A detailed history of the patient should also be obtained during 
examination to determine any past factors that could contribute to the disorder. 
For women, neurologic status, a thyroid evaluation, and a thorough pelvic and 
breast examination should be given. During the examination, the presence of any optic 
problems should be distinguished as well as scarring from past trauma to eliminate the 
possibility of neurological problems. The patient should also be checked for the presence 
of herpes zoster or any chest or breast lesions that could stimulate the production of 
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prolactin. The consistency and size of the thyroid should also be evaluated. (Jones 836) 
During the examination it is critical to check for the presence of hypothyroidism, renal 
failure, and hepatic dysfunction as a cause of elevated prolactin levels (Kaye 266). 
Hepatic dysfunction is the impaired ability of the liver to properly conduct its function in 
metabolism (On-line Medical Dictionary). It is also important to note all medications the 
patient is currently taking due to the fact that some medications can stimulate prolactin 
production producing what is referred to as pharmacologic hyperprolactinemia (Biller 
1096). If none of the previously mentioned causes ofhyperprolactinemia are apparent in 
the patient, thyroid and kidney function and liver enzymes should be tested (Kaye 266). 
For males, it is more common to present symptoms later in the course of the disorder 
with larger tumors already developed (Rebar 110I). 
If all of the previously mentioned tests reveal negative results, magnetic 
resonance imaging (MRI) or computed tomography (CT) should be conducted on the 
patient's sella turcica to determine the presence of an adenoma (Biller 1097). The sella 
turcica is the area contained at the base of the skull that holds the pituitary gland (On-line 
Medical Dictionary). A MRI generally produces better pictures of the sella and should be 
used if available. Prolactinomas less than three millimeters in diameter may not be 
detected by the MRI scan (Kaye 266), but for practical purposes the MRI will detect 
whether or not an adenoma is present. If the prolactin level ofa patient is greater than 
200 nglmL a MRI should always be performed to exclude a mass lesion (Biller & 
Luciano 1080). A MRI can reveal several different causes ofhyperprolactinemia. A 
prolactinoma could be observed as well as stalk compression or, occasionally, an 
infiltrative process involving the pituitary gland (Kaye 266). The distinction between a 
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microadenoma «Icm) and a macroadenoma (~Icm) is considered arbitrary but has been 
found very useful in diagnosis. Compared to macroadenomas, microadenomas have a 
much lower risk of increasing in size. If a microadenoma is detected it should still be 
closely monitored because it could be the beginning stages of a macroadenoma. 
Macroadenomas are also more dangerous than microadenomas due to the mass effects 
they can cause such as vision problems and headaches. Sellar lesions other than 
prolactinomas can cause hyperprolactinemia but are rather uncommon. The presence of 
other lesions should also be checked during imaging because unlike prolactinomas, which 
can usually be treated with medication, most other sellar lesions require removal using 
surgical procedures. Lesions known to increase serum prolactin levels, other than 
prolactinomas, can include germinomas, craniopharyngiomas, meningiomas, cordomas, 
and lymphocytic hypophysitis. (Biller 1098) In order to clarify these lesions, their 
definitions from the On-line Medical Dictionary are as follows: germinomas are tumors 
stemming from germ cells in the brain; craniopharyngiomas are a type of primary brain 
tumor that stems from the pituitary gland and secrete large amounts of pituitary 
hormones; and meningiomas are common benign tumors stemming from the pia­
arachnoid cells of the meninges, and can occur along the sphenoid ridge that contains the 
pituitary gland. Commonly, if a true prolactinoma is present the serum prolactin level 
corresponds with the size of the adenoma (Biller 1098). If the level of prolactin secretion 
is only mildly above average and there is a large lesion present in the patient there is a 
strong likelihood that the adenoma is not a prolactinoma and further testing should be 
considered to evaluate the lesion (Biller 1098). If all of the recommended diagnostic 
radiological and serologic examinations do not reveal the cause of elevated prolactin 
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levels the disorder is referred to as idiopathic hyperprolactinemia. Under these 
circumstances, treatment mayor may not be administered depending on symptoms and 
severity of the condition. (Kaye 266) 
As a result of all of the possible causes ofhyperprolactinemia, it can be rather 
difficult, if not impossible, to pinpoint the direct cause of the problem. Guidelines for the 
diagnosis of a patient demonstrating symptoms ofhyperprolactinemia including 
amenorrhea or irregular menses are outlined in the article Hyperprolaclinemia by James 
Jones and are as follows: 
First a pregnancy test should be done. If it is positive, elevated prolactin levels can be 
attributed to the pregnancy. If the pregnancy test is negative, follicle-stimulating 
hormone, luteinizing hormone, and prolactin levels should be measured. Follicle­
stimulating hormone is produced by the anterior pituitary and stimulates the development 
of eggs and the release of estrogens in females and the development of sperm in males; 
luteinizing hormone controls sex hormones in both females and males (On-line Medical 
Dictionary). If prolactin levels appear normal and follicle-stimulating hormone and 
luteinizing hormone levels are low or normal the patient most likely has hypothalamic 
hypogonadotropic amenorrhea. In this case the amenorrhea is not a result or symptom of 
hyperprolactinemia. If the follicle stimulating hormone levels are greater than 
40m1U/mL and prolactin levels are normal the patient may have ovarian failure. If serum 
prolactin levels are high upon initial testing a repeat of test should be done to confirm that 
the levels are consistently high. If prolactin levels remain high and follicle stimulating 
hormone levels are low or normal and luteinizing hormone levels are high the patient 
could be suffering from polycystic ovary syndrome. This syndrome is a clinical 
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syndrome characterized by amenorrhea or oligomenorrhea, anovulation and associated 
with bilateral polycystic ovaries (On-Line Medical Dictionary). If follicle stimulating 
hormone and luteinizing hormone levels are both normal or low and prolactin levels are 
high, the next step in diagnosis is testing the patient's thyroid-stimulating hormone 
(THS), triiodothyronine (T3), and thyroxine (T4) levels. THS is secreted by the anterior 
pituitary and activates cyclic AMP production in thyroid cells leading to production and 
release of thyroid hormones T3 and T4. T3 and T4 are the two main hormones produced 
by the thyroid gland (On-line Medical Dictionary). If thyroid-stimulating hormone levels 
are high and triiodothyronine and thyroxine levels are low or normal, the patient is most 
likely experiencing thyroid failure and has elevated prolactin levels as a result. IfTHS, 
T3, and T41evels are all normal or low, a CT or MRI of the sella should be conducted. If 
the sella is normal the patient is experiencing idiopathic hyperprolactinemia. If the 
patient has a pituitary lesion less than 1cm in diameter the diagnosis is a microadenoma. 
If parapituitary changes are present in the MRI or CT the patient most likely has a 
Craniopharyngioma (a primary brain tumor that develops in the pituitary gland) such as a 
sarcoidosis aneurysm. Sarcoidosis is a disease of unknown etiology in which chronic 
inflammatory granulomatous lesions are present on the pituitary gland (On-line Medical 
Dictionary). If the patient has a pituitary lesion greater than 1 cm and/or an enlargement 
or erosion of the sella the diagnosis is determined to be a macroadenoma. Another 
possible cause of elevated prolactin levels is "empty sella" syndrome. This is a condition 
of the normal or increased sella with intrasellar herniation of subarachnoid space that 
causes symptoms such as headache, visual disorders and cerebrospinal fluid rhinorrhea 
(On-line Medical Dictionary). 
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Once it has been detennined that a patient has hyperprolactinemia and the 
underlying cause(s) has been detennined or narrowed down, the correct treatment option 
for the individual must be considered. There are many guidelines for treatment due to the 
several causes and symptoms of the disorder. The main reasons treatment is indicated are 
to diminish bothersome or dangerous symptoms the patient may be experiencing and 
lower serum prolactin levels. Dopamine agonists are generally the type of treatment used 
for hyperprolactinemic patients. These agonists can reduce serum prolactin levels, 
reduce the size of prolactinomas and restore gonadal function (Webster 1105). 
Dopamine agonists function by binding to dopamine receptors and activating them (On­
line Medical Dictionary). Bromocriptine, Cabergoline, Quinagolide and Pergolide 
mesylate (Pennax) are all dopamine agonists that have demonstrated effectiveness in the 
treatment of hyperprolactinemia (Kaye 265). 
Bromocriptine mesylate (parlodel) was the first dopamine agonist to be used in 
practice in the 1970s (Webster 1105). It has been shown to reduce prolactin levels, 
inhibit prolactin secretion, and reduce the size of tumors in 70% to 100% of patients 
(Kaye 267). Bromocriptine may also produce side effects including nausea, headache 
and dizziness. Due to these adverse effects, nearly 12% ofhyperprolactinemic patients 
cannot tolerate taking the drug and must be treated by other means (Webster 1105). 
Treatment with bromocriptine should begin with 2.5 mg of the drug taken orally before 
bed. Once therapy has started the dose may be increased by 2.5 mg every week until 
normal serum prolactin levels are reached or symptoms are diminished. In general, 
patients take 2.5mg two to three times per day to achieve nonnal prolactin levels. (Kaye 
267) Bromocriptine has been the mainstay ofdopamine agonists effective in 
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hyperprolactinemia treatment. Recently two other dopamine agonists, cabergoline and 
quinagolide, have been developed and may take its place due to the adverse side effects 
and frequent administration required ofbromocriptine (Webster 1105-6). 
Cabergoline, an ergoline derivative, has a high affinity and selectivity for 
dopamine D1 receptors. This differentiates cabergoline from bromocriptine, which has an 
affinity for D, receptors. Cabergoline also has a longer half-life than bromocriptine 
allowing for once or twice weekly doses. Studies have shown that 0.6 mg of cabergoline 
is equivalent to 2.5 mg ofbromocriptine and reduces serum prolactin levels by about 
70% of the pretreatment level. (Webster 1106) The European Cabergoline Study Group 
did several studies with hyperprolactinemic females using cabergoline treatment. In one 
study, less than one percent of the patients administered cabergoline could not tolerate the 
drug, a much lower percentage than those administered bromocriptine. In another study 
3% ofthe patients discontinued use ofcabergoline due to the severity of adverse side 
effects. In the same study, more than 90% of the women who came into the study 
amenorrheic or oligomenorrheic developed regular menses and/or became pregnant 
during the study. Adverse effects of cabergoline commonly include dizziness, headache, 
nausea, weakness, and fatigue. (Webster 1106) After several more studies were done it 
was detennined that the new dopamine agonist, cabergoline, was significantly more 
effective in restoring prolactin levels and gonadal function and was tolerated better than 
bromocriptine (Webster 1107). The use ofbromocriptine is still the most widespread 
treatment of hyperprolactinemia, but cabergoline, which was developed less than a 
decade ago shows sign of being a more effective treatment for hyperprolactinemia. 
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Quinagolide is another dopamine agonist that was developed around the same 
time as cabergoline. Quinagolide is a nonergot 0 1 agonist and has a half-life in between 
that ofbromocriptine and cabergoline. Due to this, the drug can be taken once daily to 
effectively treat hyperprolactinemia (Webster 1107). In three studies conducted 
comparing bromocriptine and quinagolide, only 25 to 200 I-lg of quinagolide was needed 
per day as compared to 1.25 to 20 mg ofbromocriptine required per day for effective 
treatment. This indicates the greater efficiency of quinagolide in returning serum 
prolactin levels to the normal range. During these studies, less people had to terminate 
quinagolide treatment than bromocriptine treatment due to adverse side effects. As of 
December 1999, only one study had been conducted comparing quinagolide and 
cabergoline. In this study it appeared that quinagolide was more effective and better 
tolerated than cabergoline but more evidence is needed to effectively state quinagolide's 
superiority to cabergoline in treating hyperprolactinemia. (Webster 1108) 
Pergolide mesylate is another dopamine agonist that has shown effectiveness in 
treating hyperprolactinemia in studies. It has been shown that for treatment of 
hyperprolactinemia, pergolide is as safe and effective as bromocriptine. Pergolide is also 
more efficient that bromocriptine, only needing to be taken once daily. It is also less 
expensive. (Kaye 267) As ofDecember 1999 pergolide was licensed only for treatment 
ofParkinson's disease by the United States' Food and Drug Administration and the 
United Kingdom (Webster 1106). 
Though there are several different dopamine agonist treatments for 
hyperprolactinemia, bromocriptine is still the primary medication available in the United 
States. As of December 1999, Cabergoline was licensed only in the United Kingdom and 
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other European countries for the treatment ofhyperprolactinemia (Webster 1107). 
Dopamine agonists are generally the most popular form of treatment for 
hyperprolactinemic patients, but estrogen therapy or the use of oral contraceptives have 
also been shown to normalize serum prolactin levels. 
When determining treatment for female patients with hyperprolactinemia it is 
important to considered whether or not the patient currently desires to become pregnant. 
As mentioned, elevated prolactin levels can cause infertility for several reasons. If 
pregnancy is not desired, sometimes only observation, not treatment, is required. For 
men, if an adenoma is detected, it is important to determine its size because they are 
usually larger than those found in females. The majority of indications for therapy are 
similar in both men and women, but special consideration needs to be taken if a women 
wishes to become pregnant. 
In the article Following Patients Under Treatment for Hyperorolactinemia 
(Rebar), treatment of patients without pituitary lesions, with microadenomas, and with 
macroadenomas is considered along with the desire for pregnancy. The following 
paragraphs outline the treatment options given to physicians as described in the article by 
Robert Rebar. 
Patients without adenomas have a low risk for developing one. If pregnancy is 
not desired by the individual it is usually only necessary to observe the patient on a 
regular basis, an ongoing treatment program known as expectant management. Prolactin 
levels should be tested yearly in the patient. lflevels continue to rise, the MR1 or CT 
procedure should be repeated. For women also experiencing amenorrhea it is important 
to measure bone density during check-ups due to the risk of osteoporosis associated with 
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this condition. Dopamine agonists such as bromocriptine should be used if the patient is 
experiencing reduced bone density, symptoms of hyperprolactinemia such as irregular 
menses, or decides they want to become pregnant. Estrogen therapy may also be used to 
treat hyperprolactinemia in women who do not wish to currently become pregnant. If 
estrogen is used, prolactin levels should be measured after three months, six months, and 
one year. After the initial year, prolactin levels should be measured yearly. If prolactin 
levels continue to rise, estrogen therapy should be halted and another treatment should be 
considered. 
If a hyperprolactinemic patient with no pituitary lesion wishes to conceive, a 
dopamine agonist should be used starting at the lowest possible dose. Prolactin levels 
should be measured weekly and treatment should be used until prolactin levels return to a 
normal range. If the patient still has symptoms after prolactin levels have resumed to 
normal a different dopamine agonist could be considered or intravaginal bromocriptine 
can be used. A patient trying to conceive should use contraception until she has her first 
menstrual period. This is done in order to better determine the time of conception. As 
soon as the patient tests positive for pregnancy, use of the dopamine agonist therapy 
should be discontinued. 
A second class ofhyperprolactinemic patients are those with microadenomas 
«Icm in diameter). Ifa patient with a microadenoma does not wish to become pregnant 
and is asymptomatic and/or ovulating, oftentimes only observation is necessary. This can 
be used because microadenomas rarely grow in size. The patient must be carefully 
monitored however because at the time of the MRI the adenoma could appear less than 
one centimeter but be a developing macroadenoma. Patients with microadenomas also 
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need their bone density measured and need to be observed for any appearance of 
physiologic symptoms brought on by chronic hyperprolactinemia. Patients with 
microadenomas under expectant management should have their prolactin levels measured 
at three months, six months, twelve months, and yearly thereafter. If the physician 
decides to treat a patient with a dopamine agonist, they should be started at the 2.5 mg 
dose and gradually increase doses as explained previously. If the patient's prolactin level 
remains steady and in the normal range after one to two years of treatment, the treatment 
may be ended. After abandoning treatment the patient should be monitored yearly for the 
continuation of normal prolactin levels and normal menstruation. 
When a patient with a microadenoma desires to become pregnant, dopamine 
agonists are the best medication. As with patients without adenomas, use of medication 
should be discontinued after a positive pregnancy test. Studies have shown that there is 
little risk of pregnancy complications in women who have taken medication, but its use 
during pregnancy is still very controversial. After a woman has given birth, she may 
again need therapy to regulate prolactin levels. 
Patients diagnosed with macroadenomas (:<: I cm in diameter) are at the highest 
risk for developing mass effects due to the size of the macroadenoma and severe 
symptoms due to extremely high prolactin levels. If the patient does not wish to currently 
become pregnant, they can generally be treated with a dopamine agonist. Once the 
patient responds to therapy, prolactin levels should be tested regularly and sellar imaging 
(MRI or CT) should be conducted to monitor any sign of further adenoma growth. If the 
patient's symptoms do not dissolve, ifprolactin levels do not return to normal, or if the 
adenoma increases in size it may be necessary to refer the patient to a neurosurgeon. If 
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the patient experiences mass effects such as visual impairment or cranial nerve palsy they 
should be referred to a neurosurgeon immediately. 
If a patient with a macroadenoma desires to become pregnant dopamine agonists 
can be used, but their use is controversial. The macroadenoma may become symptomatic 
during pregnancy causing problems for the mother and possibly the fetus. If a patient has 
a macroadenoma, some physicians continue use of dopamine agonists during pregnancy 
while others do not. Though studies have shown that the drugs put the fetus at little risk, 
leaving a woman on a treatment program during pregnancy is very controversial. With 
macroadenomas, surgery before pregnancy is an option. The size of macroadenomas can 
increase during pregnancy putting the woman at an increased risk of mass effects and 
hyperprolactinemic symptoms. Partial or complete transsphenoidal resection of the mass 
may be done. It is suggested that the smallest amount possible be taken out to avoid a 
complete hypophysectomy (the surgical removal or destruction of the pituitary gland as 
defined by the On-line Medical Dictionary). It is also very important to evaluate the 
woman's pituitary function following surgery before pregnancy is attempted. 
It is important to remember that an elevated prolactin level is only a laboratory 
number. If a patient has no adverse effects from a high prolactin level, treatment is 
sometimes unnecessary. Indication for treatment, besides the desire to become pregnant, 
usually relies on symptoms such as infertility, abnormal menses, anovulation, 
galactorrhea, dysparenunia (defined as difficult or painful coitus by the On-line Medical 
Dictionary), hypogonadism, acne, hirsutism, headaches, and diminished libido (Olive 
1092). If visual field impairment or cranial nerve palsies occur in a patient, treatment 
must be administered due to the high risk of these symptoms. Treatment ranges from 
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dopamine agonist therapy to surgery depending on the individual case. For 
hyperprolactinemic patients, the goal of treatment is primarily to diminish adverse side 
effects harmful to the patient and secondly to restore normal prolactin levels. (Olive 
1093) If there are no adverse side effects due to elevated serum prolactin levels in the 
patient it may only be necessary to observe them carefully. Studies have shown that in 
some women prolactin levels can revert back to normal spontaneously. This can often be 
predicted by symptoms the patient is presenting. (Sanfilippo 1112) If chronic 
hyperprolactinemia is left untreated however, it may cause long term effects in the 
patient. Some possible long term effects of chronic hyperprolactinemia include 
osteoporosis due to loss of bone density, hypoestrogenism (decreased estrogen levels), 
the disruption of hormone functions, and mass effects if a macroadenoma is present. It is 
normally recommended that treatment with a dopamine agonist be used to treat 
hyperprolactinemic patients to avoid the possible effects of chronic hyperprolactinemia 
(Sanfilippo 1113-14). Generally, surgery is only necessary if a patient desires to become 
pregnant, has complications such as mass effects, or does not respond to medication or 
cannot tolerate the medication (Biller & Luciano 1081). Sudden hemorrhage into an 
adenoma can also occur. While this is very rare it is classified as a neurosurgical 
emergency and requires immediate surgery (Biller & Luciano 1082). 
Prolactin has been shown in several instances to playa role in autoimmune 
diseases and cause a higher incidence of autoantibodies (Steinfeld 1717). Prolactin has 
several functions in the body and is produced by several different types of cells under 
different conditions. Two autoimmune diseases in which prolactin has been implicated in 
playing a role are Sjogren's Syndrome (SS) and Systemic Lupus Erythematosus (SLE). 
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Sjogren's Syndrome is a chronic autoimmune disease characterized by lymphocytic 
infiltration into the salivary and lacrimal glands clinically leading to keratocunjunctivitis 
sicca and xerostomia (dry eyes and dry mouth) (Steinfeld 239). SLE affects mostly 
young women of childbearing age and has been observed to be sex-linked in both its 
cause and pathogenesis (Lahita 352). Prolactin is present at the sites of both of these 
diseases and plays a significant role in their pathogenesis. Understanding how prolactin 
can act in the production of auto-antibodies and continuation of autoimmune disease is 
important in understanding how to treat these diseases and exactly how prolactin 
functions in the body. 
Recent studies have implicated prolactin to be present in the salivary glands of 
Sjogren's syndrome patients. Forty-six percent of patients with primary Sjogren's 
syndrome were found to have hyperprolactinemia in a study conducted by Gutierrez et ai, 
1994 (Steinfeld 240). Evidence of hyperprolactinemia, especially that associated with the 
overproduction of big prolactin, can be a clinical sign of a more aggressive disease 
(Steinfeld 244). Big prolactin has not only been associated with SS but also with 
rheumatoid arthritis and SLE (Steinfeld 243). It was previously mentioned that prolactin 
has molecular heterogeneity. Recently, a big prolactin (60 kDa) was found to be 
neosynthesized and overexpressed in the glandular epithelial cells of minor salivary 
glands in SS patients (Steinfeld 1712). It has been suggested that prolactin induces 
autoantibody production in these patients due to the elevated levels of anti-Ro and anti­
La antibodies associated with increased prolactin in acinar epithelial cells. Ro and La are 
nuclear proteins present in humans. Prolactin has been found to act as a cytokine and has 
been demonstrated to stimulate synthesis and production of proteases in certain cells. In 
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an article entitled Prolactin Up-Regulates Cathepsin Band D Expression in Minor 
Salivary Glands ofPatients with Sjogren's Syndrome (Steinfeld), researchers investigated 
whether prolactin could modulate cathepsin Band D expression in the minor salivary 
glands of patients with SS. Cathepsins are intracellular proteolytic enzymes of animal 
tissues. Specifically, cathepsin B is a lysosomal cysteine proteinase which hydrolyzes 
proteins. Cathepsin D is an intracellular proteinase found in several tissues. It is 
involved in the catabolism of cartilage and connective tissue. (On-line Medical 
Dictionary) 
It was found that there was a positive correlation between prolactin levels and the 
production of anti-Ro and anti-La antibodies; and the level ofprolactin and the extent of 
symptoms in SS patients. According to the article, "Prolactin-like proteins are 
synthesized and overexpressed in glandular epithelial cells oflabial salivary glands from 
SS patients and correlate with the aggressiveness of the disease" (239). Patients that 
expressed extraglandular manifestations showed higher levels of prolactin than those 
patients without symptoms. It was also observed that SS patients' acinar cells of the 
minor salivary glands expressed prolactin while healthy control subjects did not. 
(Steinfeld 1716). The researchers involved in this experiment hypothesized that "the 
continuous prolactin neosynthesis in minor salivary glands of SS patients, but not in those 
of healthy subjects, might modulate the level of expression of some proteases and so lead 
to a progressive destruction of the glandular epithelial cells because of this vicious circle" 
(Steinfeld 1716). The data collected in this experiment validated this hypothesis. 
Prolactin was shown to significantly up-regulate the expression of cathepsin Band D in a 
dose-dependent fashion. Since they also showed that prolactin is neosynthesized in the 
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glandular cells of the minor salivary glands of SS patents, but not in healthy patients, it 
was concluded that the increased level of prolactin allows for the continuous expression 
of cathepsins Band D and brings their proteolytic activities into play. The increased 
proteolytic activity of cathepsins B and D is not present in healthy patients because no 
prolactin is neosynthesized in their minor salivary glands. (Steinfeld 1716) This data is 
not only significant in Sjogren's Syndrome research. Cathepsin Band D are involved in 
the pathology of several diseases including chronic inflammatory diseases of the airways 
and joints and cancer which could also implicate the involvement of prolactin in these 
diseases. Mononuclear cells infiltrating the minor salivary glands of SS patients show 
increased cathepsin B-immunoreactivity in the presence of prolactin. This suggests that 
prolactin could also modulate the biological functions of these infiltrating cells and aid in 
the destruction of tissues (Steinfeld 1717). The authors' concluded that "the prolactin 
neosynthesis, which occurs for still unknown reasons in the minor salivary glands of 
patients with Sjogren's syndrome, could playa significant part in the destruction of 
acinar structures through the activation of proteinases, including at least cathepsins Band 
D" (Steinfeld 1717). 
Hyperprolactinemia has also been associated with systemic lupus erythematosus, 
perhaps a more commonly known autoimmune disease that Sjogren's syndrome. 
Although not all SLE patients have hyperprolactinemia, elevated serum prolactin levels 
has been associated with the disease in some instances. Whether or not 
hyperprolactinemia and SLE are related is still controversial. Some researchers have 
shown positive correlation between elevated prolactin levels and SLE while others have 
shown that there is not a positive correlation between the two. While this is 
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controversial, it is known that the immune system and neuroendocrine system 
communicate through intracellular communication (Jara 748). Several studies suggest a 
link between prolactin and systemic lupus erythematosus. There is also indication that 
prolactin plays a role in the pathogenesis and clinical manifestations of SLE in humans. 
The following evidence gathered from numerous reports is presented in a review entitled 
Prolactin in Human Systemic Lupus Erythematosus (Jara) and suggests there is a 
connection between SLE and increased prolactin production: 
I. Hyperprolactinemia (HPRL), which is often mild, has been found in 20 
- 30% ofSLE patients. 
2. HPRL appears to be associated with clinical activity of SLE during 
pregnancy and in non-pregnant SLE patients...Recent clinical and 
experimental studies support the potential role of prolactin in clinical 
activity and severity of SLE. 
3. HPRL secondary to microadenoma may trigger the onset of SLE in a 
subset of patients, especially when there is mild HPRL. 
4. Defects in... dopamine metabolism, as well as the effect ofcytokines on 
prolactin secretion, may explain in part the HPRL in SLE. 
5. The findings of elevated urine PRL and urine IL-6 in active lupus 
nephritis and in cerebral spinal fluid in active central nervous system 
(eNS) involvement suggest a pathogenic role for prolactin and an 
abnormal communication between the immune and neuroendocrine 
systems in active SLE. 
(753-54) 
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While there are still several questions to be answered about the relationship 
between prolactin and SLE, there are several indications that they are somehow linked. 
While not all SLE patients demonstrate elevated prolactin levels, a significant percentage 
do. The findings from these numerous experiments suggests that prolactin may 
"participate in different local and general immune/inflammatory processes and forms a 
bridge between the neuroendocrine and immune systems in SLE" (Jara 754). 
Hyperprolactinemia is a common pituitary disorder among both men and women. 
Raised serum prolactin levels can be caused by numerous things ranging from exercise to 
an adenoma and there are a variety of different symptoms associated with the disorder. It 
can be seen in studies on ethanol and anti-psychotics that prolactin has several functions 
and hyperprolactinemia induced by the ingestion of substances is complex. 
Understanding the mechanisms which cause hyperprolactinemia is important in 
understanding how to properly treat the disorder and how to avoid taking substances that 
may aggravate the disorder. After a first blood test determines elevated prolactin levels, 
a second test should be done to confirm hyperprolactinemia. Once the diagnosis has been 
confirmed, treatment options vary depending on the individual with the disorder and their 
symptoms. Depending on the underlying cause of the disorder there are several different 
treatment options ranging from expectant management to surgery. For women, the desire 
to become pregnant is an important consideration in determining treatment. Though 
surgery is a treatment option, it is rarely used unless mass effects occur as a result of a 
macroadenoma. Generally, expectant management or treatment with a dopamine agonist 
such as bromocriptine is adequate for most patients. The purpose for treatment is to first 
diminish symptoms bothersome or harmful to the patient and secondly lower serum 
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prolactin levels. Ifhyperprolactinemia is left untreated, and elevated serum prolactin 
levels persist, adverse affects such as osteoporosis can occur. Hyperprolactinemia is a 
common disorder and can be the underlying cause of several ailments as well as a 
symptom of a greater underlying cause. Autoimmune diseases and hyperprolactinemia 
have been shown to be connected. Increased prolactin levels may worsen the 
deterioration caused by autoimmune diseases such as Sjogren's syndrome and systemic 
lupus erythematosus. It is important to understand how increased prolactin levels effect 
the progress of these diseases for proper treatment. If a patient shows signs of 
hyperprolactinemia it is important to test for, and treat, the disorder due to the adverse 
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UHON 499 Thesis Project (2) 
Fall '02: Dr. Douglas Fix's laboratory 
Background 
Mutations in the DNA of an organism can be caused by several different factors. 
Rarely, mistakes occur during DNA replication and are not repaired by any of the several 
DNA repair mechanisms. It is these un-repaired mistakes, or mutations, that over time 
can contribute to the evolution oforganisms or to diseases such as cancer. Mutagens 
such as UV radiation increase the mutation frequency in organisms causing more 
mutations to occur than in cells not exposed to any mutagens. 
UV radiation can cause pyrimidine dimers to form in between DNA nucleotides. 
A pyrimidine dimer is the chemical rearrangement ofbonds between two adjacent 
pyrimidines. There are three ways in which the rings can fuse leading to different 
dimers. The most common dimer causes the formation of a cyclobutane ring. A 
cyclobutane pyrimidine dimer (CPD) is caused by bond formation between the 5-carbon 
atoms and 6-carbon atoms of two adjacent pyrimidines. Another form of the pyrimidine 
dimer can occur when a bond is formed between the 6-carbon on one pyrimidine and the 
4-carbon on an adjacent pyrimidine. The 6-4 product has a rate ofoccurrence that is 10% 
as frequent as the cyclobutane dimer. The third photoproduct is known as TA*. This 
occurs at a frequency that is 1% of the occurrence of the CPD. When any of these dimers 
occur during replication a cell enters SOS and translesion synthesis occurs at the sight of 
the photoproduct. SOS is a response to DNA damage in which alternate genes are turned 
on for replication in order to repair the damaged DNA. During SOS, mutagenesis occurs 
at an increased rate due to the activation of alternate DNA polymerases that lack inherent 
repair mechanisms. The different dimers have been found to cause different frequencies 
ofmutation. Cyclobutane pyrimidine dimers are not highly mutagenic. 85% ofthe 
bypass events that occur as a result of a CPO do not cause a mutation. While the 6-4 and 
TA* photoproducts occur much less frequently than CPOs they are much more 
mutagenic. Only 9 - 18% of the bypass events that occur as a result of these products are 
not mutagenic. Each photoproduct has been shown to primarily cause a certain mutation. 
The cyclobutane dimer most often causes the sequence TT (T: Thymine) to mutate to TA 
(A: adenine). The 6-4 photoproduct generally causes TT to TC mutations (C: cytosine). 
The TA* product most commonly results in TA to TT mutations. 
A special type of repair system called photoreactivation exists as a repair 
mechanism for pyrimidine dimers caused by UV irradiation. This system separates the 
bound nucleotides rather than replacing them. An enzyme known as photolyase binds to 
the fused bases and can separate them. The enzyme obtains the energy needed to 
separate the bases from a reduced flavin adenine dinucleotide (FAOH2) group in the 
enzyme. FAOHz absorbs light ofwavelengths between 350 and 500nm (visible light), 
hence the name photoreactivation. The photolyase binds the dimer and the absorption of 
light causes it to cleave the bond between the two pyrimidines, restoring the bases to their 
original form. 
Escherichia coli can be manipulated in order to determine the specific mutations 
that occur as a result of pyrimidine dimers. E. coli strain FX-II is a tyrosine negative 
strain (it cannot synthesize tyrosine). This particular strain ofE. coli is Tyr- due to a 
nonsense mutation encoding a stop codon in the middle of the gene. When cells of this 
strain are exposed to UV light a portion of the cells mutate to become Tyr+ (can 
synthesize tyrosine). This is caused by back mutations that change the stop codon (UAA) 
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to another codon that allows complete translation of the gene (CAA, AAA, GAA, TTA, 
TCA, TAG, TAT, or TAC). FX-II is also excision repair deficient causing the number 
of mutations that occur to be greater than a cell with this excision repair. The increased 
frequency of mutations caused by this deficiency makes it easier to study the different 
mutations that occur as a result of dimers. This strain ofE. coli was further manipulated 
by altering the bases that surround the nonsense mutation producing a strain called FX-




Previous experimentation with this strain has shown a high degree of TA to TT mutations 
consistent with the TA* photoproduct. 
Experiments 
Over the course of the semester I worked with E. coli FX-II-AT, FX-II-AT pKY 
33, and FX-II-AT pXZ 1997. Strain FX-II-AT pKY 33 harbors a plasmid that encodes 
a CPD photolyase. The overexpression of this photolyase in the irradiated cells should 
cause fewer backmutants when the cells are exposed to visible light after they are 
exposed to UV light. Strain FX-II-AT pXZ 1997 also harbors a plasmid encoded 
photolyase. This inducible [6-4] photolyase may also cause fewer mutations to occur in 
cells exposed to visible light after UV exposure depending on the type of photoproducts 
produced. Four sets ofdata were collected using strains FX-II-AT and FX-II-AT pKY 
33 and four sets ofdata were collected using strains FX-II-AT and FX-II-AT pXZ 1997 
to determine mutation frequency after exposure to UV light and changes in frequency as 
a result of a photoreactivation. 
3 
FX-II-AT pKY 33 and FX-II-AT 
Cultures ofFX-II-AT and FX-II-AT pKY 33 were grown overnight in a 31'C 
shaker bath in 5 ml Ix A-O plus 10 ~I (microliters) tyrosine, 10 J.1I phenylalanine, and 10 
~l 20% glucose. The pKY33 media also contained 5 J.1I Ampicillin (Amp). This strain 
must be grown in media containing Amp because of the plasmid it harbors. The plasmid 
encodes an ampicillin resistance gene on it and the addition of Amp to the media ensures 
the presence of the plasmid in the cells. 
After the cells were grown overnight, the culture was diluted I :20 in fresh Ix A­
O/tyr/phe/glc and returned to the 37°C shaker bath. The optical density of the cells was 
monitored at 450 nm. The cells were grown to an optical density of0.5 and harvested. 
This took approximately three to four hours. Eight milliliters of the culture was then 
centrifuged at 3500 rpm for 25 minutes. The supernatant was discarded and the cell 
pellets were resuspended in 4 ml fresh Ix A-O. 
After resuspension in 4 ml A-O the cells were ready for exposure to UV light. 
Cells were irradiated for zero or ten seconds for each strain. Ten seconds of exposure is 
equal to I 1/m2 ofUV exposure. Fifty ~I ofeach cell suspension for each exposure time 
was spread onto search plates (plates containing nutrient broth, leucine, phenylalanine, A­
0, glucose, and agar). Two plates were prepared for each dosage in order to minimize 
pipetting errors. These plates are referred to as the Mutation plates. Spread plates were 
also prepared using dilutions of the original cultures at each time point. The suspension 
ofFX-II-AT treated with zero seconds ofUV exposure and 10 seconds ofUV exposure 
was diluted to 106 cells/ml when plated on search plates. FX-II-AT pKY 33 cells which 
received zero seconds of UV exposure were diluted 106-fold and the cells that received 
10 seconds ofUV exposure were diluted 105-fold when plated. Plates inoculated with 
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these dilutions are referred to as viability count plates and were used to count the number 
of viable cells in the cultures. Two viability plates for each strain at each dosage were 
made to take an average count of the viable cells. 
The spread plates inoculated during the UV dosage procedure were incubated for 
48 hours in a 37"C incubator. All plates were then counted. The data obtained from the 
plate counts was entered into an Excel spreadsheet that calculated the percent of viable 
cells and the mutation frequency for each UV dosage. 
After counting the mutation plates, 30 colonies from each plate were randomly 
selected and inoculated onto isolation plates (plates containing leucine, phenylalanine, 
glucose, A-O and agar). These colonies were grown overnight in a 37"C incubator. The 
colonies grown on the isolation plates were then used in a phage test to determine which 
colonies were back mutants. 
The phage test uses three T4 bacteriophages to infect cells that became tyrosine 
positive as a result of UV exposure. The T4 phage has a nonsense defect causing it to 
grow in cells containing a tRNA suppressor gene (it lyses cells with a suppressor gene). 
When this suppressor gene is present in cells, it allows them to grow on media lacking 
tyrosine as a result of suppressor mutations, not back mutations. We are looking for true 
back mutants in which the codon that was mutated to a stop codon is reverted back to a 
codon other than a stop codon by exposure to UV light. Three phages are used in this 
test, NG75, PS205, and OC427. Suspensions of the three phages were spread across the 
phage plate in one direction and cells from the isolation plates were streaked across the 









Forty fil of the phage suspension was added to the plates and a mini glass spreader was 
used to spread the suspension evenly between the walls of the plate. Bacterial cells from 
the isolation streaks were streaked in a straight line across the plate using sterile 
toothpicks. These plates were then incubated overnight at 31'C. A positive result was 
indicated by cell lysis where the phage and cells overlap. Four different outcomes were 
mainly observed in this experiment: 
75 205 427 Indication 
+ - - Back Mutant 
+ + + Suppressor Mutant 
+ - + Suppressor Mutant 
- + + Suppressor Mutant 
The isolation streaks that were observed to be back mutants during the phage test were 
re-streaked onto fresh isolation plates, incubated overnight at 37°C, and stored at 4°C for 
later use. 
FX-II-AT pXZ 1997 and FX-II-AT 
The same procedure was used to induce mutations and identify back mutants in 
strains FX-II-AT and FX-II-AT pXZ 1997 except that 30 fit ofIPTG (isopropyl-thio­
beta-D-galactoside) was added to the cultures when they reached an optical density of 0.2 
and then they were grown to aD = 0.5 and harvested. The addition of lPTG to the strain 
harboring the pXZ 1997 plasmid is necessary because the photolyase encoded on the 
plasmid is inducible. It is controlled by a lac (Irp-Iac) promoter that is turned on by the 
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addition of lPTG, a gratuitous inducer of the lac promoter. The lPTG is added when the 
optical density is 0.2 to give the cells time to produce a sufficient amount of protein. 
Several problems were encountered when I first started working with the FX-11­
AT pXZ1997 strain. First, the cells were not growing at a rate similar to that ofFX-ll­
AT without a plasmid. The previous plasmid harboring strain grew at approximately the 
same speed as the strain without the plasmid. A second observation we made was that 
the mutation frequency for the photo-reactivated plasmid strain did not differ from that of 
the plasmid strain without photo-reactivation. This was not what was expected because 
the photolyase encoded on the plasmid should repair mutations that occurred as a result 
of the UV exposure. To test the presence of the plasmid a plasmid extraction was 
preformed. After the plasmid DNA was extracted from the cells, a sample was run on an 
agarose gel along side a ladder and a sample known to contain the plasmid to determine if 
the plasmid was still in our culture. We did not see a band that corresponded to the 
expected size ofour plasmid. This plasmid extraction indicated that the plasmid that 
should have been in our pXZl997 strain may not have been present. We started again 
using a new isolate in which it was determined that the plasmid was present. 
Using the new isolate we still did not see the expected difference in mutation 
frequency between the photo-reactivated and not photo-reactivated strains ofFX-II-AT 
pXZ1997. Since we knew that our plasmid was in the cells we were using we decided to 
look at the presence of the protein in the induced cells. This was done using sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Cultures ofFX-II-AT 
and FX-II-AT pXZ 1997 were grown overnight and then inoculated into fresh media. 
Two cultures of each strain were inoculated. When the optical density of the cultures 
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reached 0.2,30 III ofITPG was added to one culture ofFX-II-AT and one culture ofFX-
II-AT pXZ 1997. All four cultures were then grown to an optical density of0.5 and 
harvested. The harvested cells were prepared for the SDS-PAGE by resuspension in a 
buffer solution and boiling for 10 minutes. The samples were loaded into the gel (6% 
running gel) and the proteins in the sample were to separated according to size. The gel 
was then stained with Coomassie Blue and then destained until the bands were visible. 
The gel showed a band at approximately 100 kDa only in the lane containing the induced 
FX-II-AT pXZ 1997 strain. This indicated that the photolyase protein was indeed being 
induced in the cells but that its presence was not affecting the frequency of mutation as 
significantly as we originally thought it would. 
Results and Discussion 
The data obtained from the viability plate counts for strains FX-II-AT pKY 33 
and FX-II-AT showed a slight decrease in survival in the strain lacking the plasmid after 
exposure to UV irradiation. When these cells were exposed to photoreaetive light the 
rate of survival did not change. The strain harboring the plasmid indicated a greater 
decease in survival when exposed to UV light. The higher mortality rate of the plasmid 
strain can be accounted for by the presence of the photolyase. The protein binds to the 
site of DNA damage after UV exposure. If the cells are not exposed to photoreactive 
light the protein remains attached to the DNA preventing the DNA polymerase from 
replicating past the damage. Cells harboring the pKY 33 plasmid exposed to 
photoreactive light (after UV exposure) showed a much higher rate of survival as was 
expected. (Figure I, panel A). 
Data collected from the phage tests using strains FX- I I-AT pKY 33 and FX- I 1-
AT is illustrated in Figure 1, panels B, C, and D. The rate ofbackmutations, Gin U 
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suppressor mutations, and Gin V suppressor mutations all increased in both strains when 
the cells were exposed to UV light. The increase in mutation frequency is a result of 
DNA damage from UV exposure. FX-II-AT pKY 33 exposed to photoreactive light 
(after UV exposure) showed fewer mutations than cells not exposed to photoreactive 
light. The photolyase in the pKY 33 strain repaired DNA damage that resulted from the 
UV radiation resulting in fewer mutations. 
Data collected from viability plate counts of strains FX-II-AT pXZ 1997 and FX-
II-AT indicated little difference in survival rates between the two strains. The presence 
of the photolyase did not seem to decrease the rate of survival in the absence of 
photoreactivation as it did in the pKY 33 strain. Photoreactivation of the plasmid strain 
did not increase the rate of survival as it did with FX-II-AT pKY 33. (Figure 2, panel A) 
The mutation frequency ofboth FX-II-AT pXZ 1997 and FX-II-AT increased 
when cells were exposed to UV radiation. The frequency of backmutations and GlnV 
suppressor mutations in the strain harboring the plasmid decreased when the cells were 
exposed to photoreactive light after UV exposure. This can be accounted for by the 
presence of the photolyase in this strain which repairs DNA damage. The frequency of 
GlnU suppressor mutations in the plasmid strain increased after photoreactivation. The 
increase in frequency was not expected. The error in this data set was larger than with 
the data collected for FX-II-AT pKY 33. (Figure 2, panels B, C, D) 
Conclusion 
Analysis of cells exposed to UV radiation showed a decrease in survival rate after 
exposure to UV light. The presence of a photolyase was shown to increase the survival 
rate of cells exposed to photoreactive light after exposure to UV light in cells harboring 
the pKY 33 plasmid. Cells harboring the pXZ 1997 plasmid did not demonstrate this 
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same increase in survival after photoreactivation. The mutation frequency was shown to 
decrease in cells encoding a photolyase after photoreactivation. This was shown in FX­
II-AT strains harboring the pKY 33 plasmid and the pXZ 1997 plasmid. I had originally 
planned on sequencing several of the back mutants isolated during the course of the 
semester to determine the exact mutations arising as a result of the UV mutagenesis. Due 
to complications that arose with the pXZ 1997 strain I did not get a chance to sequence 
any isolates. I did, however, determine that the inducible photolyase was present in 
cultures of FX- I I-AT pXZ 1997 and does not seem to significantly affect the mutation 
frequency of photoreactivated cells when compared to cells that are not photoreactivated. 
Further analysis of the backmutants isolated in this experiment will be performed to 
determine the exact mutations arising from UV irradiation ofE. coli FX- I I-AT pXZ 
1997 cells. 
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